Dolutegravir Sodium Salt-d6

Description

Dolutegravir Sodium Saltd6, is the labeled analogue of Dolutegravir Sodium Salt D528805 , a second generation HIV1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells PBMCs , MT4 cells and CIP4 cells infected with a selfinactivating PHIV lentiviral vector.